You are browsing the Hong Kong website, Regulated by Hong Kong SFC (CE number: BJA907). Investment is risky and you must be cautious when entering the market.
四環醫藥(0460.HK)拉昇暴漲23% 再創階段新高
格隆匯 02-02 14:17
格隆匯2月2日丨近期表現強勢的四環醫藥(0460.HK)午後再度快速拉昇最高漲23.16%至2.34港元,股價創2018年3月以來新高,市值221億港元。1月29日午間,公司公佈已完成對深圳市邁步機器人科技的戰略投資,持股比例為2.65%;另外,子公司軒竹生物自主研發用以治療非酒精性脂肪肝炎(NASH)的XZP-5610項目藥品已於2021年1月成功獲國家藥品監督管理局批准開展臨牀試驗。此前的1月26日,公司還宣佈收購創新驅動型生物公司康明百奧。

Follow us
Find us on Facebook, Twitter , Instagram, and YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
uSMART
Wealth Growth Made Easy
Open Account